Reproducibility update at BIO International Convention

Published 25 April 2019

BIO International Convention is considered as the largest partnering event attracting over 16,000 biotechnology and pharma leaders from around the world. The upcoming one will be held on June 3-6, 2019 in Philadelphia, PA.

EATRIS will be at the BIO-International Convention to moderate an educational session. Keynote speakers will discuss the new approaches to improve reproducibility in Biomedical Sciences.

Reproducibility is a foundational element of the scientific method, a benchmark upon which the reliability of an experiment can be tested. However, the field is facing alarmingly high irreproducibility rates as illustrated in various industry publications, with reports ranging from 50% to 80% of published results not being reproducible. It has been estimated that in the US alone, $28B in funding is spent on preclinical research that is not reproducible. This estimation does not even take into account the impact on delaying translational research and causing high failure rates observed for the development of new treatments.

To face this urgency head on, international consortia and collaborations between various stakeholders, including public-private partnerships, were formed to exchange, develop and implement quality standards and best practices. This session will examine these key findings.

The panel includes:

  • Dr. Leonard Freedman (Frederick National Laboratory for Cancer Research),
  • Dr. Nathan Coussens (NIH-NCATS)
  • Dr. Marian Hajduch (IMTM)
  • Dr. Weida Tong (NCTR/FDA)

Florence Bietrix, EATRIS Operations Manager, will moderate this session.  You can view the full agenda of this session here.